Abstracts tagged "rheumatoid arthritis (RA) and small molecules"

Abstract Number: 929 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study
Stanley Cohen¹, Katie Tuckwell ², Rebecca Kunder ², Tamiko Katsumoto ³, Rui Zhao ², Alberto Berman ⁴, Nemanja Damjanov ⁵, Dmytro Fedkov ⁶, Slawomir Jeka ⁷ and Mark Genovese ³, ¹Metroplex Clinical Research Center, Dallas, TX, ²Genentech, Inc., South San Francisco, CA, ³Stanford University, Stanford, CA, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, ⁶Bohomolets National Medical University, Kyiv, Ukraine, ⁷University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland
Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an orally administered, highly selective, non-covalent, and reversible small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK).1 We report the efficacy…
Abstract Number: 1420 • 2019 ACR/ARP Annual Meeting
Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)
Kim Lauper¹, Denis Mongin ², Sytske Anne Bergstra ³, Denis Choquette ⁴, Catalin Codreanu ⁵, Ori Elkayam ⁶, Kimme Hyrich ⁷, Florenzo Iannone ⁸, Eirik Kristianslund ⁹, Tore Kvien ¹⁰, Burkhard Leeb ¹¹, Galina Lukina ¹², Dan Nordström ¹³, Fatos Onen ¹⁴, Karel Pavelka ¹⁵, Manuel Pombo-Suarez ¹⁶, Ziga Rotar ¹⁷, Maria José Santos ¹⁸, Anja Strangfeld ¹⁹, Delphine Courvoisier ²⁰ and Axel Finckh ²⁰, ¹Division of Rheumatology, Geneva University Hospital, Switzerland / Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Geneva, Switzerland, ²Division of Rheumatology, Geneva University Hospitals, Switzerland, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ⁵Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ⁶Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel, ⁷Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom / NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, ⁸Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁰Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ¹¹Second Department of Medicine, Centre for Rheumatology Lower Austria, State Hospital Stockerau, Stockerau, Austria., Stockerau, Austria, ¹²V.A.Nasonova Research Institute of Rheumatology, Moscow, Russian Federation., Moscow, Russia, ¹³Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ¹⁴Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ¹⁶Rheumatology Service , Hospital Clinico Universitario , Santiago de Compostela , Spain., Santiago de Compostela, Spain, ¹⁷UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹⁸Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁹German Rheumatism Research Center (DRFZ), Berlin, Germany, ²⁰Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland
Background/Purpose: In many countries, JAK-inhibitors (JAKi) have been recently accepted for the treatment of patients with rheumatoid arthritis (RA). However, prescription patterns may differ notably…
Abstract Number: 16L • 2017 ACR/ARHP Annual Meeting
Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs
Philip J Mease¹, Joel Kremer², Stanley Cohen³, Jeffrey R Curtis⁴, Christina Charles-Schoeman⁵, Edward V Loftus⁶, Jeffrey D Greenberg⁷, Niki Palmetto⁸, Keith S Kanik⁹, Daniela Graham⁹, Cunshan Wang⁹, Pinaki Biswas⁸, Gary Chan¹⁰, Ryan DeMasi¹⁰, Hernan Valdez⁸, Thijs Hendrikx¹⁰ and Thomas V Jones¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ³Metroplex Clinical Research Center, Dallas, TX, ⁴University of Alabama, Birmingham, AL, ⁵University of California, Los Angeles, CA, ⁶Mayo Clinic, Rochester, MN, ⁷Corrona, LLC, Southborough, MA, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk…
Abstract Number: 81 • 2017 ACR/ARHP Annual Meeting
Selective Inhibition of the Immunoproteasome Subunit LMP7 Is Not Sufficient for Blocking Cytokine Production or Attenuating Progression of Experimental Arthritis
Eric Lowe¹, Janet Anderl¹, R Andrea Fan¹, Henry W. B. Johnson², Christopher J Kirk³ and Tony Muchamuel⁴, ¹Biology, Kezar Life Sciences, South San Francisco, CA, ²Medicinal Chemistry, Kezar Life Sciences, South San Francisco, CA, ³Kezar Life Sciences, South San Francisco, CA, ⁴Pharmacology and Toxicology, Kezar Life Sciences, South San Francisco, CA
Background/Purpose: The proteasome inhibitor (PI) PR-957/ONX 0914 blocks cytokine production in vitro and attenuates disease progression in experimental models of rheumatoid arthritis (RA) (Nature Medicine…
Abstract Number: 531 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tofacitinib Versus Baricitinib in Rheumatoid Arthritis Using a Systematic Review and Network Meta-Analysis of Randomized Trials
Natalia Zamora^1,2,3, Maria A. Lopez-Olivo¹, Jean Tayar¹, Robin Christensen² and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, Copenhagen, Denmark, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina
Background/Purpose: To explore the comparative effectiveness of tofacitinib or baricitinib in patients with rheumatoid arthritis (RA) following a systematic review of randomized trials, by performing…
Abstract Number: 2627 • 2016 ACR/ARHP Annual Meeting
The Effect of Fostamatinib with Methotrexate on Circulating Biomarkers of Synovium, Cartilage and Bone Metabolism: Potential Utility for Clinical Development Decision Making in Rheumatoid Arthriti
Adam Platt¹, Anne C. Bay-Jensen², Martin Braddock³, Martin Jenkins⁴, Kishwar Musa⁵, Christian S. Thudium⁶, Cecilie F. Kjelgaard-Petersen⁶, Emma Graham³, Sue Keeler³, Gill Slynn³, Michael Weinblatt⁷ and Morten Asser Karsdal², ¹Diagnostic Development, AstraZeneca, Cheshire, United Kingdom, ²Rheumatology, Nordic Bioscience, Herlev, Denmark, ³AstraZeneca, Macclesfield, United Kingdom, ⁴Research & Development, AstraZeneca, Macclesfield, United Kingdom, ⁵Laboratory, Nordic Bioscience, Herlev, Denmark, ⁶Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Fostamatinib was developed for the treatment of RA and improved signs and symptoms of RA 1, but did not improve modified Total Sharp Score…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].